Embla Medical hf (EMBLA) Stock Overview
Provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EMBLA from our risk checks.
EMBLA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Embla Medical hf. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 27.45 |
| 52 Week High | DKK 37.90 |
| 52 Week Low | DKK 25.00 |
| Beta | 0.46 |
| 1 Month Change | 1.11% |
| 3 Month Change | -7.26% |
| 1 Year Change | -17.81% |
| 3 Year Change | -11.88% |
| 5 Year Change | -39.14% |
| Change since IPO | 399.09% |
Recent News & Updates
Narrative Update • May 19
EMBLA: Share Cancellations And Renewed Capital Authorisations Will Support Future Upside
Analysts have kept their DKK price target for Embla Medical hf. broadly steady at DKK 33.3, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions in their updated models.Narrative Update • Apr 30
EMBLA: Share Cancellations And Capital Authorisations Will Support Future Upside
Analysts have trimmed their price target on Embla Medical hf. to DKK 33.30 from DKK 37.40, citing updated assumptions around a slightly higher discount rate, more moderate revenue growth of 8.40% and a lower future P/E of about 21x, while keeping profit margin expectations broadly in line.
Narrative Update • Apr 08
EMBLA: Capital Reduction And Buybacks Will Support Future Upside Potential
Analysts have modestly lifted their price target for Embla Medical hf. to DKK 34.0, reflecting slightly updated assumptions around discount rate, revenue growth, profit margin and future P/E.Narrative Update • Mar 25
EMBLA: Capital Reduction And Buybacks Will Support Attractive Long Term Upside
Analysts have kept the fair value estimate for Embla Medical hf. steady at DKK 34.00.Recent updates
Narrative Update • May 19
EMBLA: Share Cancellations And Renewed Capital Authorisations Will Support Future Upside
Analysts have kept their DKK price target for Embla Medical hf. broadly steady at DKK 33.3, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions in their updated models.Narrative Update • Apr 30
EMBLA: Share Cancellations And Capital Authorisations Will Support Future Upside
Analysts have trimmed their price target on Embla Medical hf. to DKK 33.30 from DKK 37.40, citing updated assumptions around a slightly higher discount rate, more moderate revenue growth of 8.40% and a lower future P/E of about 21x, while keeping profit margin expectations broadly in line.Narrative Update • Apr 08
EMBLA: Capital Reduction And Buybacks Will Support Future Upside Potential
Analysts have modestly lifted their price target for Embla Medical hf. to DKK 34.0, reflecting slightly updated assumptions around discount rate, revenue growth, profit margin and future P/E.Narrative Update • Mar 25
EMBLA: Capital Reduction And Buybacks Will Support Attractive Long Term Upside
Analysts have kept the fair value estimate for Embla Medical hf. steady at DKK 34.00.Narrative Update • Mar 10
EMBLA: Share Cancellations And New Capital Authorisations Will Support Future Upside
Analysts have kept their DKK 37.40 price target for Embla Medical hf unchanged. They cite only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions that do not materially alter their view of fair value.Narrative Update • Feb 23
EMBLA: Share Cancellations And Buybacks Will Support Future Upside Potential
Analysts have kept their DKK price target for Embla Medical hf broadly stable at around DKK 37.4, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that slightly adjust the risk and earnings profile without changing their overall valuation view. What's in the News The Annual General Meeting on 10 March 2026 will vote on reducing share capital by cancelling 2,441,257 treasury shares of ISK 1 each, equal to 0.57% of current share capital, with a corresponding update to Article 4 of the Articles of Association (Key Developments).Narrative Update • Feb 09
EMBLA: New Share Repurchase Program Will Support Upside Potential
Narrative Update on Embla Medical hf Analysts have modestly adjusted their price target for Embla Medical hf, keeping fair value steady at $37.40 while fine tuning assumptions such as a slightly higher discount rate, a marginally lower revenue growth outlook, a small reduction in expected profit margin, and a slightly higher future P/E. These changes reflect a more balanced view of risk and earnings potential.Analysis Article • Feb 06
Embla Medical hf. (CPH:EMBLA) Just Released Its Full-Year Earnings: Here's What Analysts Think
Shareholders might have noticed that Embla Medical hf. ( CPH:EMBLA ) filed its full-year result this time last week...Narrative Update • Jan 25
EMBLA: Buybacks And Ukraine Initiative Will Support Steady Future Outlook
Analysts have kept their fair value estimate for Embla Medical hf. steady at €34.00.Narrative Update • Jan 11
EMBLA: Ukraine Program And Buybacks Will Support Future Margin Stability
Analysts have kept their fair value estimate for Embla Medical hf unchanged at €34.00. They have updated assumptions around discount rate, revenue growth, profit margins and future P/E to reflect a slightly different balance of risk and profitability in their models.Narrative Update • Dec 19
EMBLA: Ukraine Expansion And Margin Outlook Will Support Steady Future Performance
Analysts have raised their price target for Embla Medical hf. from approximately 28.00 dollars to 34.00 dollars, reflecting expectations for slightly faster revenue growth, improving profit margins, and a higher justified future earnings multiple, despite a modestly higher discount rate.Narrative Update • Dec 05
EMBLA: Share Buyback And Ukraine Mobility Initiative Will Support Steady Outlook
Analysts have modestly raised their price target on Embla Medical hf., reflecting slightly lower perceived risk, a marginal uptick in long term profit margins, and a small increase in the expected future earnings multiple, while keeping their overall fair value estimate broadly unchanged at approximately $37.40 per share. What's in the News Opened a new prosthetic clinic in Kyiv as part of the three year "Iceland Supports Mobility in Ukraine" initiative, which targets high quality prosthetic care and rehabilitation for up to 1,000 Ukrainian amputees (Key Developments) Announced that the Ukraine initiative, co financed with the Government of Iceland and implemented with charity partner Future for Ukraine (FFU), has a total estimated value of USD 11 million over three years (Key Developments) Reiterated full year 2025 guidance for 5 to 6% organic sales growth, indicating confidence in near term demand and execution (Key Developments) Completed a share buyback tranche totaling 1,449,010 shares, or about 0.34% of shares outstanding, for USD 7 million under the program announced on February 7, 2025 (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at approximately $37.40 per share, indicating no material shift in the overall valuation outcome.Analysis Article • Dec 04
Here's Why We Think Embla Medical hf (CPH:EMBLA) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • Nov 20
EMBLA: Share Buyback And Kyiv Clinic Launch Will Support Bullish Outlook
Analysts have maintained their target price for Embla Medical hf. at €37.40, citing minor adjustments to discount rates and future market assumptions, but no significant change in company fundamentals.Analysis Article • Nov 07
Does Embla Medical hf (CPH:EMBLA) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Narrative Update • Nov 05
EMBLA: Stable Outlook Will Reflect Earnings Guidance and Recent Share Buyback Completion
Analysts have maintained their price target for Embla Medical hf. at €37.40.Narrative Update • Oct 22
Analysts Lift Embla Medical hf Price Target on Stronger Growth and Improved Margins
Analysts have raised their price target for Embla Medical hf. from $35.65 to $37.40, citing improved revenue growth and higher profit margin forecasts.Analysis Article • Sep 23
Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Key Insights Embla Medical hf's estimated fair value is kr.39.84 based on 2 Stage Free Cash Flow to Equity Embla...Narrative Update • Sep 19
Portfolio Expansion And Reimbursement Coverage Will Strengthen Medtech Future
The consensus Analyst Price Target for Embla Medical hf has risen to DKK35.65, primarily reflecting a substantial increase in the future P/E ratio while net profit margin remains stable. What's in the News Completed repurchase of 923,277 shares (0.22%) for $4.3 million under previously announced buyback.Analysis Article • Sep 03
Investors Interested In Embla Medical hf.'s (CPH:EMBLA) Earnings
Embla Medical hf.'s ( CPH:EMBLA ) price-to-earnings (or "P/E") ratio of 28.7x might make it look like a strong sell...Analysis Article • Aug 08
Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?
CPSE:EMBLA 1 Year Share Price vs Fair Value Explore Embla Medical hf's Fair Values from the Community and select yours...Analysis Article • Jul 25
Analysts Are Updating Their Embla Medical hf. (CPH:EMBLA) Estimates After Its Second-Quarter Results
The quarterly results for Embla Medical hf. ( CPH:EMBLA ) were released last week, making it a good time to revisit its...Analysis Article • Jul 10
Is Embla Medical hf (CPH:EMBLA) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jun 10
Slowing Rates Of Return At Embla Medical hf (CPH:EMBLA) Leave Little Room For Excitement
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • May 26
A Look At The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Embla Medical hf fair value estimate is kr.35.58 Current share...Analysis Article • Apr 11
Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 24.3x Embla Medical hf. ( CPH:EMBLA ) may be sending very bearish signals...Analysis Article • Mar 27
Here's Why Embla Medical hf (CPH:EMBLA) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Mar 06
Embla Medical hf.'s (CPH:EMBLA) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Embla Medical hf's Annual General Meeting to take place on 12th of March Salary of US$576.0k is part of...Analysis Article • Feb 23
Investors Met With Slowing Returns on Capital At Embla Medical hf (CPH:EMBLA)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
New Narrative • Feb 09
Acquisition Of Fior & Gentz And New Product Launches Will Expand Neuro Orthotics Portfolio Into New Markets
Expansion into new markets with Fior & Gentz acquisition could boost revenue and market share through neuro orthotics.Analysis Article • Feb 09
Embla Medical hf. Just Missed EPS By 5.8%: Here's What Analysts Think Will Happen Next
Embla Medical hf. ( CPH:EMBLA ) came out with its annual results last week, and we wanted to see how the business is...Analysis Article • Jan 25
A Look At The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Embla Medical hf fair value estimate is kr.39.19 With kr.34.00...Analysis Article • Jan 03
We Ran A Stock Scan For Earnings Growth And Embla Medical hf (CPH:EMBLA) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Dec 16
Shareholders Should Be Pleased With Embla Medical hf.'s (CPH:EMBLA) Price
With a price-to-earnings (or "P/E") ratio of 30.9x Embla Medical hf. ( CPH:EMBLA ) may be sending very bearish signals...Analysis Article • Nov 30
Embla Medical hf (CPH:EMBLA) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Oct 25
Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts
Investors in Embla Medical hf. ( CPH:EMBLA ) had a good week, as its shares rose 3.8% to close at kr.35.20 following...Analysis Article • Oct 17
Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Embla Medical hf fair value estimate is kr.41.46 With kr.34.00...Analysis Article • Oct 02
Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Aug 22
Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Analysis Article • Jul 26
Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for Embla Medical hf. ( CPH:EMBLA ) shareholders, because the company has just released its...Analysis Article • Jul 17
Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)
Key Insights The projected fair value for Embla Medical hf is kr.33.24 based on 2 Stage Free Cash Flow to Equity With...Analysis Article • May 14
Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 14x, you may consider...Analysis Article • Apr 26
Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Embla Medical hf. ( CPH:EMBLA ) last week reported its latest first-quarter results, which makes it a good time for...Analysis Article • Apr 10
A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Embla Medical hf fair value estimate is kr.29.98 Embla Medical...Analysis Article • Mar 23
Is Össur hf (CPH:OSSR) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jan 21
Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Analysis Article • Jan 03
Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)
Key Insights The projected fair value for Össur hf is kr.28.71 based on 2 Stage Free Cash Flow to Equity With kr.26.60...Analysis Article • Nov 28
Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Nov 08
Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Sep 23
A Look At The Fair Value Of Össur hf. (CPH:OSSR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Össur hf fair value estimate is kr.32.80 With kr.29.00 share...Shareholder Returns
| EMBLA | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | -0.4% | -0.6% | -1.0% |
| 1Y | -17.8% | -28.4% | -18.4% |
Return vs Industry: EMBLA exceeded the Danish Medical Equipment industry which returned -28.4% over the past year.
Return vs Market: EMBLA matched the Danish Market which returned -18.4% over the past year.
Price Volatility
| EMBLA volatility | |
|---|---|
| EMBLA Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DK Market | 9.0% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: EMBLA has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: EMBLA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 4,500 | Sveinn Solvason | www.emblamedical.com |
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints.
Embla Medical hf. Fundamentals Summary
| EMBLA fundamental statistics | |
|---|---|
| Market cap | DKK 11.71b |
| Earnings (TTM) | DKK 555.35m |
| Revenue (TTM) | DKK 6.21b |
21.1x
P/E Ratio1.9x
P/S RatioIs EMBLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBLA income statement (TTM) | |
|---|---|
| Revenue | US$958.30m |
| Cost of Revenue | US$364.46m |
| Gross Profit | US$593.84m |
| Other Expenses | US$508.21m |
| Earnings | US$85.63m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 21, 2026
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 61.97% |
| Net Profit Margin | 8.94% |
| Debt/Equity Ratio | 41.3% |
How did EMBLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/06 01:40 |
| End of Day Share Price | 2026/06/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Embla Medical hf. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Beatrice Fairbairn | Berenberg |